Jagiellonian University

Morris Animal Foundation selects 10 fellowship studies for funding

Retrieved on: 
Tuesday, May 30, 2023
Ohio State University, White-nose syndrome, Yale University, University, Fungal infection, University of Illinois Urbana-Champaign, Horse, Colorado State University, Infection, Osteosarcoma, Escherichia coli, University of California, Jagiellonian University, Biomarker, Gene expression, University of Georgia, Abdominal cavity, Urinary tract infection, Animal, Investment, Tuberculosis, Risk, Dog, Systemic inflammatory response syndrome, Blood, University of Wisconsin–Madison, Morris Animal Foundation, McIntosh, Health, Air pollution, Disease, Vaccine, Agriculture

DENVER, May 30, 2023 /PRNewswire/ -- Morris Animal Foundation announced it is funding 10 new fellowship studies, with two of the studies funded by longtime donor Sally R. McIntosh.

Key Points: 
  • DENVER, May 30, 2023 /PRNewswire/ -- Morris Animal Foundation announced it is funding 10 new fellowship studies, with two of the studies funded by longtime donor Sally R. McIntosh.
  • The studies will focus on a variety of topics, including deadly infections in dogs, immune response disorders in horses and amphibian conservation.
  • "Our Fellowship Training program is one of the most impactful investments we can make for animal health research," said Dr. Kathy Tietje, Chief Program Officer at Morris Animal Foundation.
  • McIntosh made her first gift to Morris Animal Foundation to advance greyhound health research in 2009 and since then, has expanded her support into other areas of animal health research, including wildlife health.

Tai Ji Men’s Bell of World Peace and Love Rings in Silicon Valley

Retrieved on: 
Friday, September 2, 2022
Tao, Culture, Technology, SAN, Gautama Buddha, Academy, City, CESNUR, United Nations, UN, Human rights, GLOBE, Jagiellonian University, Taipei Economic and Cultural Representative Office, Fear, International, Silicon, Risk, Adoption, Center, Education, First Nations in Ontario, Love, Friends, Government, Federalisation of the European Union, Qigong, Movement, Area studies, Ambassador, Climate change, Society, Consciousness, Anxiety, Atmosphere, Speech, International Day of Conscience, Goodwill, Martial arts, Social isolation, Health, Freedom, Smoke, Tai chi, Civilization, Nobel Peace Prize, Goal, Foundation, Happiness, Soteria, Man, Bell, Environment, Life, Nightclub, Tourism, Entertainment, Film, Conscience

Congressman Ro Khanna after he rang Tai Ji Mens Bell of World Peace and Love.

Key Points: 
  • Congressman Ro Khanna after he rang Tai Ji Mens Bell of World Peace and Love.
  • Fremont Mayor Lily Mei presented a certificate of recognition to Dr. Hong, Tao-Tze, the leader of Tai Ji Men, congratulating and commending Tai Ji Men .
  • On this special occasion, a video was played featuring the highlights of Tai Ji Mens recent ceremonies of ringing the Bell of World Peace and Love.
  • Tai Ji Men Qigong Academy : Tai Ji Men is an ancient menpai (similar to school) of qigong, martial arts, and self-cultivation.

WPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed Project

Retrieved on: 
Monday, March 7, 2022
Recurrence, Patient, Consortium, Research, Complementarity, Radiation therapy, Hospital, FSE, Prognosis, Biotechnology, WPD, University, NPS, CSE, CRAN, Efficiency, The Consortium Agreement of 1954, Nanoparticle, Glioblastoma, GBM, Brain, Institute, Information science, NH, Neoplasm, Cell, European Innovation Council, Oslo University Hospital, Wake Forest University, Jagiellonian University, Automation, Radiation, CNRS, University of Lorraine, Virology, National Scientific and Technical Research Council, Tissue, GLOBE, Research institute, Pharmaceutical industry, Medical imaging, Nanomedicine

VANCOUVER, British Columbia, March 07, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the Company or WPD) a clinical-stage pharmaceutical company, is excited to announce that it has received the final version of the signed Consortium Agreement related to the EuroNanoMed Project.

Key Points: 
  • VANCOUVER, British Columbia, March 07, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the Company or WPD) a clinical-stage pharmaceutical company, is excited to announce that it has received the final version of the signed Consortium Agreement related to the EuroNanoMed Project.
  • Over the three-year project timeline, the consortium aims to plan and adapt the X-ray doses given to the patient to maximize radiotherapy efficiency on these high-grade tumors while preserving the adjacent healthy tissue.
  • This project will base its work on pre-clinical experiments at different biological scales (cells, tissues, and in vivo on rodent models) and algorithms' development.
  • The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes about 29 countries in Europe and Asia, including Russia, depending on the compound.

Immunicom Announces Promising Preliminary Data from its Immunopheresis® Study in Late-Stage Cancer and Metastatic Melanoma Patients Presented at 2021 SITC Congress

Retrieved on: 
Tuesday, December 7, 2021
Oncology, Medical Devices, Health, Clinical Trials, Pharmaceutical, Biotechnology, Health, Principal investigator, Technology, Cancer, Clalit Health Services, CEO, Nivolumab, CE marking, Blood, Publication, Rabin Medical Center, Food, Patient, Multimedia, ISO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Jagiellonian University, Immunotherapy, Society for Immunotherapy of Cancer, Plasma, Melanoma, Certification, FDA, Society, Degenerative disease, Congress, TNBC, Toxicity, Immune system, Newsweek, Safety, Quality of life, TNF, Large-cell lung carcinoma, PD-L1, Sheba Medical Center, MD, Clinical trial, Survival, Doctor of Philosophy, Hospital, SITC, Pharmaceutical industry, Vaccine, Medical device, Immunicom, Sheba Medical Center at Tel Hashomer, IMMUNICOM, SHEBA MEDICAL CENTER AT TEL HASHOMER

By depleting TNF receptors from plasma, this therapy is designed to free the cytokine TNF-alpha, thereby unleashing its potent anti-cancer effects.

Key Points: 
  • By depleting TNF receptors from plasma, this therapy is designed to free the cytokine TNF-alpha, thereby unleashing its potent anti-cancer effects.
  • Preliminary data were presented from Part A (Immunopheresis therapy alone) from six patientsthree with melanoma, and three with triple negative breast cancer (TNBC)who have failed multiple prior lines of standard chemo and immunotherapies.
  • Of these six heavily pretreated patients, three completed the 12-week study regimen, and three were withdrawn due to clinical progression.
  • Immunopheresis therapy was well-tolerated in these late-stage patients, and no treatment-related serious adverse events were reported.

Appfire Appoints Christine Alpers as General Counsel

Retrieved on: 
Thursday, November 11, 2021
Professional Services, Technology, Legal, Other Technology, Mobile, Wireless, Software, University, Faculty of Law and Administration of the Jagiellonian University, Suffolk University Law School, COO, IT service management, University of Massachusetts, Software, Lead, Workflow, Sale, Jagiellonian University, Automation, Security Administrator Tool for Analyzing Networks, Publishing, Business intelligence, General counsel, TIBCO, Vista Equity Partners, Management

Appfire , a leading provider of software that helps teams solve modern challenges with digital solutions, announced today that Christine Alpers has joined the company as General Counsel, to lead and scale the companys global legal strategy and function.

Key Points: 
  • Appfire , a leading provider of software that helps teams solve modern challenges with digital solutions, announced today that Christine Alpers has joined the company as General Counsel, to lead and scale the companys global legal strategy and function.
  • Christine brings more than 25 years of corporate legal experience spanning both privately held and public technology companies.
  • She most recently served as General Counsel at Acquia, where she oversaw all legal matters across the companys global operation, including the $1 billion sale of Acquia to Vista Equity Partners.
  • Appfire is an award-winning Atlassian Platinum Marketplace Partner and a global authority in the Atlassian ecosystem for 16 years.

Immunicom Presents Promising Preliminary Data from Immunopheresis® Studies in Late-Stage Cancer Patients at JCA-AACR 2021

Retrieved on: 
Tuesday, September 14, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Education, Association, American Association, Immune system, Patient, Renal cell carcinoma, Japanese Cancer Association, Large-cell lung carcinoma, Jagiellonian University, Degenerative disease, Research, AACR, Science, American Association for Cancer Research, Antibody, ISO, Conference, Medicine, Toxicity, NSCLC, Radiation, Diagnosis, CE marking, Cancer, Principal investigator, Immunotherapy, Food, Bristol Myers Squibb, FDA, Protein, Japanese Association of Medical Sciences, Cytokine, Certification, Quality of life, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TNBC, Technology, Doctor of Philosophy, Risk, Clinical trial, Sheba Medical Center, JCA, Cancer Science, Multimedia, Pharmaceutical industry, Vaccine, Medical device, Immunicom, JCA and AACR, IMMUNICOM, JCA AND AACR

Immunicom, Inc ., a clinical-stage biotechnology company pioneering subtractive advanced cancer therapies, presented promising preliminary data from trials investigating Immunopheresis therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy.

Key Points: 
  • Immunicom, Inc ., a clinical-stage biotechnology company pioneering subtractive advanced cancer therapies, presented promising preliminary data from trials investigating Immunopheresis therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy.
  • Immunicoms ongoing clinical trials are in the most difficult to treat, late-stage cancer patients.
  • Immunicoms novel Immunopheresis therapy uses its proprietary subtractive LW-02 column to selectively remove immune-suppressive cytokines produced by cancer tumors.
  • Standard cancer treatments are surgery, radiation or those that typically require the infusion of drugs, antibodies or proteins into the patient.

Ryvu Therapeutics Has Completed the Construction of the R&D Center for Innovative Drugs

Retrieved on: 
Tuesday, June 2, 2020
Operating systems, Computer architecture, Proprietary software, Jagiellonian University, Solaris, Synchrotron radiation, Synchrotron

Construction of own R&D Centre constitutes an element of execution of the strategic plans focused on the discovery and development of innovative therapies announced in 2017.

Key Points: 
  • Construction of own R&D Centre constitutes an element of execution of the strategic plans focused on the discovery and development of innovative therapies announced in 2017.
  • The R&D Center for Innovative Drugs is situated in close proximity to the Jagiellonian University as well as Solaris Synchrotron Facility.
  • The initiative to honor Dr. Sternbach, was spearheaded by Ryvu and received strong support from Krakow scientific and technology community.
  • Its launch will allow Ryvu to expand the pipeline and accelerate research process of innovative drugs.